In 2023, the treatment success rate for patients with extensively drug-resistant tuberculosis (XDR-TB) in the UK stood at approximately 42%. Based on the forecasted data, this rate is expected to improve gradually, reaching 50% by 2028. The year-on-year percentage change indicates a steady improvement of about 1-2% annually from 2024 to 2028. The compound annual growth rate (CAGR) for this period suggests an average annual increase of approximately 3.5% in treatment success rates from 2024 to 2028.
Future trends to watch include the impact of new treatment protocols, developments in drug discovery, and innovations in healthcare delivery. Monitoring these aspects will provide insights into potentially accelerating improvements in treatment success rates for XDR-TB in the UK beyond 2028.
